Macquarie and Cisco to Host SD-WAN Tech Talk
SAN JOSE, Calif., Aug. 22, 2018 (GLOBE NEWSWIRE) -- Cisco will host a conference call with Macquarie and Cisco’s Ramesh Prabagaran, Senior Director of Product Management, SD-WAN Enterprise Routing. The discussion will focus on Cisco’s SD-WAN strategy and differentiated offerings for enterprise routing. Interested parties can find more information on Cisco's Investor Relations website at https://investor.cisco.com/.
No new financial information will be discussed on this conference call.
Date: Wednesday, September 5, 2018
Time: 9:00 am PT / 12:00 pm ET
Speaker: Ramesh Prabagaran, Senior Director of Product Management, SD-WAN Enterprise Routing
Moderator: Srini Pajjuri, Analyst, Macquarie
Participant Dial in:
Toll Free: 877-674-0754
International Number: 702-696-4605
This event will be webcast and a replay will be available one month after the event. Interested parties can view this event on Cisco's Investor Relations website at investor.cisco.com.
Cisco (NASDAQ: CSCO) is the worldwide technology leader that has been making the Internet work since 1984. Our people, products, and partners help society securely connect and seize tomorrow's digital opportunity today. Discover more at newsroom.cisco.com and follow us on Twitter at @Cisco.
Cisco and the Cisco logo are trademarks or registered trademarks of Cisco and/or its affiliates in the U.S. and other countries. A listing of Cisco's trademarks can be found at www.cisco.com/go/trademarks.
RSS Feed for Cisco: http://newsroom.cisco.com/rss-feeds
|Investor Relations Contact:||Press Contact:|
|Gloria Lee||Robyn Blum|
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Saniona selects highly promising preclinical candidate with broad potential in autoimmune disorders22.7.2019 08:00:00 CEST | Press release
PRESS RELEASE July 22, 2019 Preclinical candidate SAN903 to be developed to Phase 1 clinical study in 18 months First-in-class compound with a new mode-of-action and strong IP Saniona AB (OMX: SANION) today announces that it has selected a new development candidate, SAN903, for preclinical development, which can enter clinical Phase 1 in only 18 months. Based on work done to date, Saniona has elected to focus SAN903 initially on the treatment of Crohn’s disease and colitis. “SAN903, which is generated from our advanced ion channel platform, is a first-in-class product and, we believe, has the potential to transform the treatment paradigm for severe autoimmune diseases, including Crohn’s disease and colitis. We look forward to bringing this exciting asset to the stage of Phase 1 first-in-man clinical studies in early 2021,” said Jørgen Drejer, CEO of Saniona. With SAN903, Saniona has identified a novel proprietary IK channel inhibitor that effectively dampens gut inflammation and can be
PCI Biotech: Extension of preclinical research collaboration agreement with a top-10 large pharma company22.7.2019 08:00:00 CEST | Press release
Oslo (Norway), 22 July 2019 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company today announced that they are extending the preclinical research collaboration with an undisclosed top-10 pharma company. The pharma company is one of the global leaders in nucleic acid therapeutics and the collaboration was initiated in September 2015. The aim of the extension is to further evaluate the synergistic effects of both parties' technology platforms in an in vivo setting and to determine whether PCI Biotech's fimaNAc technology has the potential to enhance the therapeutic effect of the partner's nucleic acid therapeutic compounds. The research collaboration is extended with 6 months until the end of 2019 and the companies have agreed to thereafter use the following 6 months (until end June 2020) to evaluate the potential for a further partnership. Contact information: Per Walday, CEO email@example.com Mobile: +47 917 93 429 About PCI Biotech PCI Biotech is a biopharmaceutical co
Saniona väljer mycket lovande preklinisk kandidat med bred potential i autoimmuna störningar22.7.2019 08:00:00 CEST | Pressemelding
PRESSMEDDELANDE 22 juli 2019 Preklinisk kandidat SAN903 ska utvecklas till fas 1 inom 18 månader First-in-class substans med ny verkningsmekanism och starkt IP Saniona AB (OMX: SANION) meddelar idag att det har valt en ny läkemedelskandidat SAN903, för preklinisk utveckling som är tänkt att gå in i kliniska fas 1-studier inom 18 månader. Baserat på det forskningsarbete som utförts har Saniona valt att inledningsvis fokusera SAN903 på behandlingen av Crohns sjukdom och kolit. "SAN903, som genererats från vår avancerade jonkanalplattform, är en first-in-class substans och vi tror att den har potential att ändra behandlingsparadigmen för allvarliga autoimmuna sjukdomar inklusive Crohns sjukdom och kolit. Vi ser fram emot att ta denna spännande substans till kliniska fas 1-studier i början av 2021”, säger Jørgen Drejer, vd för Saniona. Med SAN903 har Saniona identifierat en ny proprietär IK-kanalinhibitor som effektivt dämpar tarminflammation och kan användas för behandling av inflammatori
BinckBank publishes its half year report 201922.7.2019 07:15:00 CEST | Press release
Highlights of the first half year 2019 Saxo Bank has extended the initial offer period during which shareholders can submit their shares under the Offer to 31 July 2019. The process for obtaining regulatory approvals is on schedule. As mentioned before, the expectation remains that the transaction with Saxo Bank will be completed during the first half of Q3 2019. Net result 19H1 € 6.6 million (18H1: € 22.2 million). Net earnings per share 19H1 € 0.10 (18H1: € 0.33). The result for 18H1 included the profit on the sale of Think ETF Asset Management B.V. (€ 8.1 million, € 0.12 per share). No interim dividend will be paid for the first half of 2019. Number of transactions 19H1 in line with 18H1 at 5.0 million transactions (+1%). Assets under management at the end of 19H1 amounted to € 1.0 billion (18H1: € 1.0 billion). Assets under management of the new propositions rose to € 239 million (18H1: € 142 million). Turning point to net inflow almost reached. Attachment 2019-Q2 half year report
Clariant AG: Clariant signs an agreement regarding the sale of its Healthcare Packaging Business22.7.2019 07:00:00 CEST | Press release
Divestment of Clariant’s Healthcare Packaging Business to Arsenal Capital Partners Total consideration of approx. CHF 308 million Muttenz, July 22, 2019 - Clariant, a focused and innovative specialty chemical company, has signed an agreement with respect to the sale of its Healthcare Packaging business to a newly-formed affiliate of Arsenal Capital Partners. The total consideration of the sale amounts to approximately CHF 308 million payable at closing, which is expected in Q4 2019. The total consideration is equivalent to 13.2 times adjusted FY2018 EBITDA. The closing of the transaction is subject to customary conditions and approvals. Clariant’s Healthcare Packaging business offers products used to protect pharmaceutical products from moisture and oxygen. This includes customizable, high-quality drop-in products (canisters and packets), Integrated Desiccant Systems and specially designed plastic bottles containing oxygen barrier materials. In 2018, the Healthcare Packaging business g
Schibsted ASA (SCHA/SCHB) - Mandatory Notification of Trade22.7.2019 07:00:00 CEST | Press release
Stiftelsen Tinius, through Blommenholm Industrier AS, has on 19 July 2019 acquired 80,458 B-shares in Schibsted ASA (the “Company”), at a price of NOK 219.5039 per share. After this transaction Blommenholm Industrier owns 28,188,589 A-shares and 29,734,382 B-shares in the Company. Stiftelsen Tinius and Blommenholm Industrier AS is represented in the board of the Company by Ole Jacob Sunde. Oslo, 19 July 2019 This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act